2026. Effect of Hormone Resistance Type on First-Line Treatment Selection in ER+/HER2-Negative Metastatic Breast Cancer. Voprosy onkologii. 72, 3 (Jul. 2026), OF-2675. DOI:https://doi.org/10.37469/0507-3758-2026-72-3-OF-2675.